Cargando…
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
BACKGROUND: A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy. MATERIALS AND METHODS: We carried out a retrospective analysis of prospectively collected data from consecutive patients with non-viral advanced HCC, treated with atez...
Ejemplares similares
-
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
por: Rimini, M., et al.
Publicado: (2021) -
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma
por: Miyahara, K, et al.
Publicado: (2013) -
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma
por: Rapposelli, I.G., et al.
Publicado: (2021) -
Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma
por: Toshikuni, N, et al.
Publicado: (2000) -
Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma
por: Kariyama, K, et al.
Publicado: (1999)